PAX5 and precursor B-cell acute lymphoblastic leukemia: This strategy of eliminating preleukemic cells by the JAK-STAT inhibition using ruxolitinib indicates the potential utility of a similar strategy for children who are susceptible to developing B-ALL due to PAX5 genetic susceptibility or other inherited mutations that render the preleukemic cells reliant on this signaling pathway.